**Author details**




Cell cultures enable one to perform investigation on models: - in vitro (mass screening,




Natural products can be considered as promising drugs for anti-atherosclerotic therapy. Two-year treatment with Allicor (garlic powder) has a direct anti-atherosclerotic effect on carotid atherosclerosis in asymptomatic men. Inflaminat (calendula, elder and violet), pos‐ sessing anti-cytokine activity, caused regression of carotid atherosclerosis as a result of 1 year treatment of asymptomatic men. Phytoestrogen-rich drug Karinat (garlic powder, extract of grape seeds, green tea leafs, hop cones, β-carotene, α-tocopherol and ascorbic

Our basic studies have shown that cellular lipidosis is the principal event in genesis of athe‐ rosclerotic lesion. Using cellular models and natural products we have developed an ap‐ proach to prevent lipid accumulation in arterial cells. This led to regression of atherosclerosis and/or prevention of its progression in patients. So, our basic findings were successfully translated into clinical practice. As a result of this translation novel approach to anti-atherosclerotic therapy was developed. On the basis of our knowledge we developed drugs possessing direct anti-atherosclerotic activity. Our clinical trial confirmed the efficacy

acid) prevented development of carotid atherosclerosis in postmenopausal women.

This work was supported by the Russian Ministry of Education and Science.


The in vitro and ex vivo models can be employed to reveal and investigate of:

taglandins, antioxidants, lipostabil, mushrooms, mollusk meat, etc.);


glandins, - blockers, antioxidants, etc.);

study of the mechanism of drug action);

sults obtained on in vitro and ex vivo models.


both novel approach and novel drugs.

**Acknowledgements**

blockers, calcium antagonists, mushrooms, krill meat).

antagonists and lovastatin);

206 Current Trends in Atherogenesis

rooms, krill meat);

Alexander N. Orekhov1\*, Igor A. Sobenin2 , Alexandra A. Melnichenko3 , Veronika A. Myasoedova1 and Yuri V. Bobryshev4,1

\*Address all correspondence to: a.h.opexob@gmail.com

1 Institute for Atherosclerosis Research, Skolkovo Innovative Center, Moscow, Russia

2 Russian Cardiology Research and Production Complex, Ministry of Healthcare and Social Development, Moscow, Russia

3 Institute of General Pathology and Pathophysiology, Russian Academy of Medical Scien‐ ces, Moscow, Russia

4 Faculty of Medicine, School of Medical Sciences, University of New South Wales, Sydney, Australia
